The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]
Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Articles by Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
5